Communiqués OptiNose, Inc.

Actions

OPTN

US68404V1008

Temps réel estimé Cboe BZX Autres places de cotation 16:49:25 16/07/2024			Varia. 5j.	Varia. 1 janv.
1,165 ^USD	-8,27 %		+9,86 %	-9,30 %

27/06	Optinose annonce l'élargissement de l'accès à XHANCE avec l'ajout aux formulaires commerciaux nationaux	CI
14/05	Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Expanded Access to XHANCE with Addition to National Commercial Formularies	27/06	AQ
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	17/05	AQ
OptiNose: Q1 Earnings Snapshot	14/05	AQ
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights	14/05	AQ
Optinose Announces Reporting Date for First Quarter 2024 Financial Results	10/05	AQ
Optinose Announces $55 Million Registered Direct Offering	09/05	AQ
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million	25/04	AQ
Optinose to Present at the Needham Virtual Healthcare Conference	04/04	AQ
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps	15/03	AQ
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?	14/03	PR
OptiNose: Q4 Earnings Snapshot	07/03	AQ
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights	07/03	AQ
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results	29/02	AQ
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice	18/01	AQ
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE	06/12	AQ
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference	22/11	AQ
OptiNose: Q3 Earnings Snapshot	09/11	AQ
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates	09/11	AQ
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results	27/10/23	AQ
Optinose to Present at the 2023 Cantor Global Healthcare Conference	22/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués OptiNose, Inc.

Actions

OPTN

US68404V1008

Communiqués

Filtres